Novo Nordisk nach Split WKN: A3EU6F ISIN: DK0062498333 Kürzel: NOV Forum: Aktien User: Coronaprofiteur

Ich wünsche die 50 hält und es geht auf die 60

Nachbörslicher Handel bei den Amis jetzt schon +3% auf Tradingview, natürlich könnte er Abverkauf werden aber ich denke das wird 😂 mal schauen

Denke sieht ganz gut aus 😁

Na dann lass es doch krachen und Dippen , dann wird nachgekauft die news sind doch gut . 😉✌️

9 Uhr wird's nach unten krachen mit Gewinnmitnahmen. Aber egal 😌

Jetzt haben wir die 50€ fürs erste geknackt, vorausgesetzt es gibt keinen fetten 9 Uhr Dip in Kopenhagen.

Schlecht gealtert morgen 😂

Und rauf geht’s https://robinhood.com/us/en/stocks/NVO/

In February, Novo Nordisk submitted a New Drug Application (NDA) for the once-daily pill formulation of Wegovy®.2* The FDA review of this NDA is anticipated to be completed by the end of this year.5 Currently, there are no approved oral formulations of a GLP-1 medicine for weight loss. If approved by the FDA, the pill for weight management will be fully made in the US, with production already underway at Novo Nordisk’s significantly expanded manufacturing facility.

When looking at the effect regardless of whether the participants took the medicine exactly as they should, people taking oral semaglutide 25 mg still achieved an average weight loss of 13.6% versus 2.2% with the placebo.1*** Close to a third (29.7%) had a weight loss of 20% or more versus 3.3% for placebo.1*** Additionally, the study also found that oral semaglutide 25 mg improved cardiovascular risk factors, as well as the ability to be more active in daily life, compared to placebo. This was consistent with previous trial results of injectable Wegovy®.1,3

Novo Nordisk’s oral semaglutide 25 mg (Wegovy® in a pill*) delivered 16.6% weight loss in people with obesity in a newly published study Oral semaglutide 25 mg (the once-daily pill formulation of Wegovy®) achieved significant weight loss, with one in three study participants losing 20% or more body weight1** Oral semaglutide 25 mg also demonstrated improvements in the ability to perform everyday physical activities such as bending, standing, walking, being physically active, and improvements in cardiovascular risk factors1 Oral semaglutide 25 mg is the first oral GLP-1 therapy submitted to the US Food and Drug Administration (FDA) for chronic weight management,2 and Novo Nordisk has already begun production at its US sites